Treatment of inflammation and/or endotoxic shock

Abstract

This invention provides the use of one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for treatment of inflammation and/or endotoxic shock and/or treatment of wounds and/or reduction of levels of inflammatory chemokines in a subject, and one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for use in the treatment of inflammation and/or endotoxic shock, and/or wounds, or for the reduction of levels of inflammatory mediators.

1 - 3 . (canceled) 
     
     
         4 . A method of treating, preventing or ameliorating inflammation, a wound or endotoxic shock in a subject comprising administering to the subject one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof. 
     
     
         5 . (canceled) 
     
     
         6 . The method of  claim 4 , wherein the level of one or more inflammatory mediators in a subject is reduced. 
     
     
         7 . The method of  claim 6 , wherein the one or more inflammatory mediators are selected from the group comprising TNFα, IL-1α, IL-1β, IL-6, IL-12, G-CSF, MCP-2 (CCL8), GROα ((CXCL1), GROβ (CXCL2), IL-8 (CXCL8), TECK (CCL25), MCP-1 (CCL2), interferon γ and Rantes (CCL5). 
     
     
         8 - 10 . (canceled) 
     
     
         11 . The method of  claim 4 , wherein the peptide is between about 5 and about 30 amino acids. 
     
     
         12 . The method of  claim 11 , wherein the peptide comprises between about 5 and about 30 amino acids derived from the C-terminal end of a Chemerin protein, or an analog or a derivative thereof. 
     
     
         13 . The method of  claim 12 , wherein the peptide derived from the C-terminal end of a Chemerin protein has at least 30% or higher identity with the natural occurring C-terminal end of the Chemerin protein. 
     
     
         14 . The method of  claim 13 , wherein the peptide has at least 30% sequence identity with between the last 5 and the last 30 amino acids of the Chemerin protein according to Seq ID no: 31 (human sequence) or Seq ID no: 34 (mouse sequence). 
     
     
         15 . The method of  claim 14 , wherein the analog or derivative has at least about 50% of the anti-inflammatory activity, and/or the anti-endotoxic shock activity, and/or the inflammatory mediator level reducing activity, of a peptide having a naturally occurring sequence. 
     
     
         16 . The method of  claim 15 , wherein one or more of the peptides has the sequence of Seq ID No: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30 or is an analog or derivative thereof; or
 the use or method of claim wherein one or more of the peptides has the sequence of Seq ID No: 37 and 38 or is an analog or derivative thereof.   
     
     
         17 . The method of  claim 15 , wherein the peptide has at least 30% sequence identity with one or more peptides of Seq ID No: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30; or
 the use or method of  claim 16  wherein the peptide has at least 30% sequence identity with one or more peptides of Seq ID No: 37 or 38.   
     
     
         18 . The method of  claim 4 , wherein the peptide analog or derivative comprises a small molecule mimetic of a peptide derived from the C-terminal end of a Chemerin protein. 
     
     
         19 . The method of  claim 18 , wherein the peptide, or analog or derivative thereof, is intended for administration at a dose of between about 10 pg/kg and about 1 mg/kg. 
     
     
         20 . The method of  claim 19 , wherein the peptide, or analog or derivative thereof, is intended for administration at a dose of between about 10 pg/kg and about 100 ng/kg. 
     
     
         21 . A medical device, wound dressing, or bandage impregnated with one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof. 
     
     
         22 - 25 . (canceled) 
     
     
         26 . A peptide having the sequence of Seq ID No: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 or an analog or derivative thereof; or
 a peptide having the sequence of Seq ID No: 37 or 38 or an analog or derivative thereof.   
     
     
         27 - 28 . (canceled) 
     
     
         29 . A pharmaceutical composition comprising one or more of the peptides of  claim 26  and a pharmaceutically acceptable diluent, carrier or excipient. 
     
     
         30 . The medical device, wound dressing, or bandage of  claim 21 , wherein the one or more peptides is selected from the sequences of Seq ID No: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 37, or 38, an analog or derivative thereof. 
     
     
         31 . The medical device, wound dressing, or bandage of  claim 30 , wherein the one or more peptides includes a peptide having the sequence of Seq ID No: 37 or 38 or an analog or derivative thereof.